What Grofibrat Treats: Main Uses and Benefits

Grofibrat is primarily indicated as a supportive measure alongside diet to help address specific types of high fat levels in the blood, a condition often referred to as dyslipidemia. This medicine has approved uses in two key therapeutic areas. One primary use is to assist in lowering elevated triglyceride levels in adults with markedly high concentrations. The other main indication is to help diminish elevated low-density lipoprotein cholesterol in adults with high cholesterol when other standard lipid-lowering therapies may not be suitable or tolerated. The common clinical application involves using Grofibrat to support changes in lipid markers and work toward recommended blood fat levels. The essential benefit is the support in maintaining healthy lipid profiles when lifestyle changes alone are insufficient.

Quick Fact: Relief for Elevated Triglycerides

Eligibility Map: Who can and cannot use Grofibrat — Official Regulatory Information

This medication is primarily indicated for use in adult patients with certain lipid disorders. However, use is strictly prohibited or highly restricted in specific populations due to potential risks, as defined by regulatory documents.

Regulatory agencies define the eligibility profile by placing significant constraints on individuals with impaired organ function, particularly severe kidney or active liver disease, where use is universally contraindicated. Additionally, the drug is prohibited for nursing mothers and those with specific allergy histories. Use in patients with mild-to-moderate renal impairment is permitted only with a reduced dose and careful monitoring, establishing kidney function as a central factor in determining appropriate patient use.

Interactions with other medicines and products

Grofibrat's official interaction profile, as defined by regulatory authorities, centers on several critical combinations and pharmacokinetic restrictions.

Interaction Scope

Population-Specific Notes: The regulatory labeling specifically identifies the risk of myopathy when combined with statins as being heightened in elderly patients, and those with renal failure or uncontrolled hypothyroidism.

Official Context: The interaction profile establishes strict regulatory limitations, including a formal contraindication for co-administration with other fibrates. It requires specific procedural constraints, such as mandatory dose adjustments and monitoring for anticoagulants, and timing rules to ensure proper absorption with other medicines.

Grofibrat's primary mechanism involves activating the Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha). This nuclear receptor activation triggers the transcription of specific genes that regulate lipid metabolism.

Activation of PPARalpha increases the synthesis and expression of lipoprotein lipase (LPL), an enzyme that facilitates the hydrolysis of triglycerides within circulating chylomicrons and very-low-density lipoproteins (VLDL). Concurrently, the drug modulates hepatic synthesis, decreasing the production and secretion of VLDL particles by inhibiting apoB synthesis.

Furthermore, this action enhances reverse cholesterol transport. The increased transcription of apoAI and apoAII contributes to an alteration in lipoprotein composition and promotes cellular cholesterol efflux. These molecular events collectively result in the modulation of circulating lipoprotein and apolipoprotein concentrations.

Grofibrat contains the active substance fenofibrate and is used as an adjunct to diet to manage high cholesterol (hypercholesterolemia) and high triglycerides (severe hypertriglyceridemia) in adults.

General Administration Guidelines

• Dosage: Always take this medication exactly as prescribed by your doctor. Dosing is individualized based on your response and laboratory tests.
• Frequency: Grofibrat is typically taken once per day.
• Method: Swallow the tablet whole. Do not crush, break, dissolve, or chew the tablet, as this can affect its absorption.

Note: Doses are often adjusted based on lipid test results, typically at 4 to 8-week intervals. If your condition does not improve after two months of treatment, your doctor may discontinue the medication.

Important Considerations

• Diet and Lifestyle: Grofibrat is only one part of a total treatment program that must include a proper low-fat, low-cholesterol diet and regular exercise as recommended by your healthcare provider.
• Missed Dose: If you miss a dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
• Drug Interactions: If you are taking a bile acid binding resin (e.g., cholestyramine), take Grofibrat at least one hour before or four to six hours after the resin to prevent reduced absorption of Grofibrat. Your doctor will also closely monitor you if you are taking blood-thinning medication (coumarin anticoagulants), as Grofibrat can potentiate its effects.

Research Evidence / Overview of Studies for Grofibrat

1. Evidence for Managing Abnormal Blood Fat Levels (Dyslipidemia)

Research exploring Grofibrat's role in managing high blood fat levels, known as dyslipidemia, primarily involves large-scale, long-term Randomized Controlled Trials (RCTs). These studies included thousands of adult participants, particularly those with Type 2 Diabetes Mellitus, who were often already receiving standard cholesterol-lowering medications like statins. The research examined changes in specific fat markers, such as triglycerides and HDL cholesterol (the "good" cholesterol), as well as monitoring the occurrence of major health outcomes like heart attacks and strokes.

Studies consistently reported that Grofibrat was associated with measured changes in blood fat markers. Specifically, findings described patterns related to changes in triglycerides and increases in HDL cholesterol during the study periods. However, when researchers monitored the overall occurrence of the primary hard outcome—the composite rate of Major Adverse Cardiovascular Events (MACE) across the entire population of patients with Type 2 Diabetes—the main trial results did not describe a significant difference between the Grofibrat group and the control group.

2. Evidence for Effects on Microvascular Complications

Research has explored whether Grofibrat was associated with patterns related to certain small-vessel health issues, known as microvascular complications. Studies monitored the progression of Diabetic Retinopathy (eye damage linked to diabetes) as a specific outcome. This evidence was often derived from pre-specified analyses within the same large-scale, long-term RCTs that focused on heart health, but also included dedicated research focusing on ocular outcomes.

Analyses across the major long-term trials described patterns in the rates of progression for diabetic retinopathy severity in the populations studied. Furthermore, research describes patterns in the observed frequency of the need for certain types of laser interventions or treatments for eye disease in the Grofibrat groups compared to control groups over the study duration. These findings help contextualize how diabetic eye complications evolved in the observed populations. The extent to which the observed pattern is related to the drug's primary action on blood fats, remains uncertain.

3. What Remains Uncertain or Requires Further Study

Research has explored various facets of Grofibrat's use, but some key areas of uncertainty remain. The overall evidence for its role in Major Adverse Cardiovascular Events in the general population of patients with Type 2 Diabetes is mixed, and the primary analyses of the major trials did not describe a significant difference in outcomes. Research examining whether Grofibrat was associated with patterns related to the clinical outcome of acute pancreatitis in patients with severe hypertriglyceridemia lacks dedicated, large-scale trial evidence. Certain subgroup findings are also considered uncertain because they require confirmation through specific, large research studies designed just for those subsets.

Key Studies & References Effect of combination therapy with fenofibrate and simvastatin on cardiovascular events in type 2 diabetes: the ACCORD Study Group

Common questions about Grofibrat (FAQ)

Q: Can I take Grofibrat if I have kidney problems?

A: Official regulatory documents indicate that Grofibrat is contraindicated (not recommended for use) if you have severe kidney impairment, including if you are on dialysis. For patients with mild to moderate kidney problems, use in this group is permitted only with a reduced dose and careful monitoring, which your physician will determine based on your specific condition.

Q: Is Grofibrat safe to use during pregnancy?

A: Grofibrat is generally not recommended for use while pregnant. Official product information indicates that use during pregnancy is typically reserved for situations where the potential benefit is considered to justify the possible risk to the fetus, as there is limited data on its effects during human pregnancy.

Q: What should I do if I vomit after taking my daily dose?

A: Official drug labeling does not provide specific instructions for redosing if a patient vomits immediately after taking Grofibrat. The instructions provided for a missed dose advise skipping the dose and resuming the regular schedule the following day. If this situation occurs, guidance from a healthcare provider should be sought.

Q: Can I take Grofibrat with food?

A: Whether Grofibrat should be taken with food depends on the specific formulation prescribed. Official administration guidelines state that some forms of fenofibrate must be taken with food, as this can affect its absorption. Always follow the precise instructions provided on your prescription label for the specific product.

Q: How should I store Grofibrat while traveling internationally?

A: Official regulatory documents specify that the product must be stored at controlled room temperature, which is typically between 20 C and 25 C. When traveling, the product should be kept in its original container and protected from excessive heat and moisture to maintain its stability and ensure effectiveness.

How to Store and Dispose of Grofibrat

Grofibrat (fenofibrate) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Requirements

Disposal Instructions

Any unused or expired Grofibrat must be disposed of in accordance with local requirements. The medicine should generally not be flushed down the toilet or poured down a drain. Follow local drug take-back programs or the official guidance for safe disposal in household trash.